[ad_1]
This “Melodysplastic Syndrome (MDS) Therapeutic Drug Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Major Players, Competitive Strategies and Forecasts, 2021-2029” Report has been added to ResearchAndMarkets.com provide.
This report covers in-depth data related to the MDS therapeutic drug market. The report covers the overall analysis related to market segments based on drug categories (hypomethylation drugs, immunomodulatory drugs, growth factors, etc.) and different regions.
Myelodysplastic syndrome (MDS) is a cancer that is considered a group of blood and bone marrow diseases that involves the production of abnormal and immature blood cells. It is expected that the MDS therapeutic drug market will experience significant market growth during the forecast period due to the increase in the prevalence of MDS, the increase in medical system expenditures, the increase in investment in MDS treatment research and development, and the large number of ideal pipeline drugs.
The launch of late-stage pipeline drugs such as JNJ-63935937, MLN-4924, NSC-39069 and rigosertib is expected to drive significant market growth during the 2021-2029.1q forecast period
Companies mentioned
-
Celator Pharmaceuticals (Jazz Pharmaceuticals plc.)
-
Bayer
-
Shinji co., ltd.
-
Cell Therapy Company
-
Incyte Corporation
-
Janssen Biotechnology Company
-
MedImmune LLC (AstraZeneca)
-
Millennium Pharmaceuticals (Takeda Pharmaceutical)
-
Novartis
-
Onconova Therapeutics Inc.
-
Pfizer
-
Taihe Pharmaceutical (Otsuka Holdings)
Key topics covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3. Myelodysplastic Syndrome (MDS) Therapeutics: Market Dynamics and Outlook
3.1. Market definition and overview
3.2. Driver
3.3. Challenge
3.4. Opportunity
3.5. Attractive investment advice, divided by region
3.6. Competitive landscape
3.6.1. The competitive landscape of major players in 2020
Chapter 4 Analysis of the pipeline of treatment drugs for myelodysplastic syndrome (MDS)
4.1. Overview
4.2. Pipeline analysis of Phase 3 drugs
4.3. Table display of Phase 1 and Phase 2 drugs
Chapter 5. Global Myelodysplastic Syndrome (MDS) Therapeutic Drug Market by Drug Category, 2019-2029 (Million USD)
5.1. Overview
5.2. Attractive investment proposals, by drug category, 2020
5.3. Hypomethylating agent
5.3.1. Azacitidine
5.3.2. Decitabine
5.4. Immunomodulatory drugs
5.4.1. Lenalidomide
5.5. Growth factors
5.5.1. Epoetin Alpha
5.5.2. Darbepoetin Alpha
5.5.3. Filgrastim
5.6. Other
5.6.1. Cytarabine
5.6.2. Daunorubicin
5.6.3. Idabycin
5.6.4. Topotecan
5.6.5. Fludarabine
Chapter 6. Global Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Regions, 2019-2029 (Millions of USD)
6.1. Overview
6.2. North American Myelodysplastic Syndrome (MDS) Therapeutic Drug Market Analysis, 2019-2029
6.2.1. North American Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Drug Category, 2019-2029 (Million USD)
6.2.2. North American Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Country, 2019-2029 (Million USD)
6.2.2.1. We
6.2.2.2. Canada
6.3. 2019-2029 European Myelodysplastic Syndrome (MDS) Therapeutic Drug Market Analysis
6.3.1. European Myelodysplastic Syndrome (MDS) therapeutic drug market, by drug category, 2019-2029 (Millions of dollars)
6.3.2. European Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Country, 2019-2029 (Million USD)
6.3.2.1. United Kingdom
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. 2019-2029 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutic Drug Market Analysis
6.4.1. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutic Drug Market by Drug Category from 2019 to 2029 (Million USD)
6.4.2. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Country, 2019-2029 (Millions of USD)
6.4.2.1. China
6.4.2.2. Japan
6.4.2.3. Rest of the Asia-Pacific region
6.5. Latin America Myelodysplastic Syndrome (MDS) Therapeutic Drug Market Analysis, 2019-2029
6.5.1. Latin America Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Drug Category, 2019-2029 (Million USD)
6.5.2. Latin America Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Country, 2019-2029 (Millions of USD)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. The rest of Latin America
6.6. Middle East and Africa (MEA) Myelodysplastic Syndrome (MDS) Therapeutic Drug Market Analysis, 2015-2025
6.6.1. MEA Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Drug Category, 2019-2029 (Million USD)
6.6.2. MEA Myelodysplastic Syndrome (MDS) Therapeutic Drug Market, By Regions, 2019-2029 (Million USD)
6.6.2.1. Gulf Cooperation Council
6.6.2.2. Other MEAs
Chapter 7 Company Profile
7.1. Bayer
7.1.1. Business description
7.1.2. Financial information (subject to data availability)
7.1.3. Drug category combination
7.1.4. Major developments
7.2. Celator Pharmaceuticals (Jazz Pharmaceuticals plc.)
7.3. New Foundation
7.4. Cell Therapy Company
7.5. Daiichi Sankyo Co., Ltd.
7.6. Inset Company
7.7. Janssen Biotechnology Company
7.8. MedImmune, LLC (AstraZeneca)
7.9. Millennium Pharmaceuticals (Takeda Pharmaceutical)
7.10. Novartis
7.11. Onconova Therapeutics, Inc.
7.12. Pfizer
7.13. Taihe Pharmaceutical (Otsuka Holdings)
7.14. Other famous players
For more information about this report, please visit https://www.researchandmarkets.com/r/yfjtek
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210616005657/en/
[ad_2]
Source link
